[{"query_translation":"\"1 palmitoyl 2 oleoyl sn glycero 3 phospho rac 1 glycerol\"[Title/Abstract]","search_time":"2025-06-29T09:09:34.09","drug_name":"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))","translation_set":[],"indication":"Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin which was indicated for the prevention of respiratory distress syndrome in premature infants.","status":"success","count":28,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%221-Palmitoyl-2-oleoyl-sn-glycero-3-%28phospho-rac-%281-glycerol%29%29%22%5BTIAB%5D%20OR%20%221-Palmitoyl-2-oleoyl-sn-glycero-3-%28phospho-rac-%281-glycerol%29%29%22%5BMeSH%20Terms%5D","original_query":"\"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[TIAB] OR \"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[MeSH Terms]","retmax":10,"query":"\"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[TIAB] OR \"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[MeSH Terms]","pmids":["17323171","19167304","10600889","15853943","25759169","33839361","28597209","18205118","21595453","19580334"]},{"query_translation":"\"2 2 dibenzothiazyl disulfide\"[Title/Abstract]","search_time":"2025-06-29T09:09:34.77","drug_name":"2,2'-Dibenzothiazyl disulfide","translation_set":[],"indication":"2,2'-Dibenzothiazyl disulfide is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.","status":"success","count":1,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%222%2C2%27-Dibenzothiazyl%20disulfide%22%5BTIAB%5D%20OR%20%222%2C2%27-Dibenzothiazyl%20disulfide%22%5BMeSH%20Terms%5D","original_query":"\"2,2'-Dibenzothiazyl disulfide\"[TIAB] OR \"2,2'-Dibenzothiazyl disulfide\"[MeSH Terms]","retmax":1,"query":"\"2,2'-Dibenzothiazyl disulfide\"[TIAB] OR \"2,2'-Dibenzothiazyl disulfide\"[MeSH Terms]","pmids":["8750898"]},{"query_translation":"\"4 isopropylamino diphenylamine\"[Title/Abstract]","search_time":"2025-06-29T09:09:35.401","drug_name":"4-(Isopropylamino)diphenylamine","translation_set":[],"indication":"4-(Isopropylamino)diphenylamine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.","status":"success","count":1,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%224-%28Isopropylamino%29diphenylamine%22%5BTIAB%5D%20OR%20%224-%28Isopropylamino%29diphenylamine%22%5BMeSH%20Terms%5D","original_query":"\"4-(Isopropylamino)diphenylamine\"[TIAB] OR \"4-(Isopropylamino)diphenylamine\"[MeSH Terms]","retmax":1,"query":"\"4-(Isopropylamino)diphenylamine\"[TIAB] OR \"4-(Isopropylamino)diphenylamine\"[MeSH Terms]","pmids":["37015229"]},{"query_translation":"\"Abacavir\"[Title/Abstract]","search_time":"2025-06-29T09:09:36.058","drug_name":"Abacavir","translation_set":[],"indication":"Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection.[L30400] It is available in a combination product alongside [dolutegravir] and [lamivudine] for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.[L41365]","status":"success","count":2532,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abacavir%22%5BTIAB%5D%20OR%20%22Abacavir%22%5BMeSH%20Terms%5D","original_query":"\"Abacavir\"[TIAB] OR \"Abacavir\"[MeSH Terms]","retmax":10,"query":"\"Abacavir\"[TIAB] OR \"Abacavir\"[MeSH Terms]","pmids":["9585869","30000607","30725802","32809632","31643550","18536095","27260856","30730651","27054757","25017682"]},{"query_translation":"\"Abaloparatide\"[Title/Abstract]","search_time":"2025-06-29T09:09:36.721","drug_name":"Abaloparatide","translation_set":[],"indication":"Abaloparatide is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) [L740,L44737] or patients who have failed or are intolerant to other available osteoporosis therapy.[L740] In postmenopausal women with osteoporosis, abaloparatide reduces the risk of vertebral and nonvertebral fractures.[L740] Abaloparatide is also indicated to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy.[L740]","status":"success","count":328,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abaloparatide%22%5BTIAB%5D%20OR%20%22Abaloparatide%22%5BMeSH%20Terms%5D","original_query":"\"Abaloparatide\"[TIAB] OR \"Abaloparatide\"[MeSH Terms]","retmax":10,"query":"\"Abaloparatide\"[TIAB] OR \"Abaloparatide\"[MeSH Terms]","pmids":["35478046","36592455","32773051","30696576","25905277","27533157","35279261","31674644","39120740","37130601"]},{"query_translation":"\"Abametapir\"[Title/Abstract]","search_time":"2025-06-29T09:09:37.378","drug_name":"Abametapir","translation_set":[],"indication":"Abametapir is indicated, in the context of an overall lice management program, for the topical treatment of head lice infestation in patients 6 months of age and older.[L15153]","status":"success","count":10,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abametapir%22%5BTIAB%5D%20OR%20%22Abametapir%22%5BMeSH%20Terms%5D","original_query":"\"Abametapir\"[TIAB] OR \"Abametapir\"[MeSH Terms]","retmax":10,"query":"\"Abametapir\"[TIAB] OR \"Abametapir\"[MeSH Terms]","pmids":["38905531","34157881","36552044","29999197","35839355","34074914","30828591","40309371","28082644","35082036"]},{"query_translation":"\"Abarelix\"[Title/Abstract]","search_time":"2025-06-29T09:09:38.038","drug_name":"Abarelix","translation_set":[],"indication":"For palliative treatment of advanced prostate cancer.","status":"success","count":55,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abarelix%22%5BTIAB%5D%20OR%20%22Abarelix%22%5BMeSH%20Terms%5D","original_query":"\"Abarelix\"[TIAB] OR \"Abarelix\"[MeSH Terms]","retmax":10,"query":"\"Abarelix\"[TIAB] OR \"Abarelix\"[MeSH Terms]","pmids":["12757402","28870102","17155895","20053189","11342922","12092009","22416801","22093775","24775720","16986005"]},{"query_translation":"\"Abatacept\"[Title/Abstract] OR \"Abatacept\"[MeSH Terms]","search_time":"2025-06-29T09:09:38.73","drug_name":"Abatacept","translation_set":[],"indication":"Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and in patients ≥2 years of age for the treatment of active psoriatic arthritis.[L48811] In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.[L20504] Abatacept is also indicated for the prophylaxis of acute graft-versus-host disease, in combination with [methotrexate] and a calcineurin inhibitor such as [tacrolimus], in patients two years of age and older who are undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.[L20504]","status":"success","count":4830,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abatacept%22%5BTIAB%5D%20OR%20%22Abatacept%22%5BMeSH%20Terms%5D","original_query":"\"Abatacept\"[TIAB] OR \"Abatacept\"[MeSH Terms]","retmax":10,"query":"\"Abatacept\"[TIAB] OR \"Abatacept\"[MeSH Terms]","pmids":["33053283","36815259","37595759","37423647","35121155","35462572","36920087","36280095","38364839","35705376"]},{"query_translation":"\"Abciximab\"[Title/Abstract] OR \"Abciximab\"[MeSH Terms]","search_time":"2025-06-29T09:09:39.485","drug_name":"Abciximab","translation_set":[],"indication":"Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.","status":"success","count":2778,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abciximab%22%5BTIAB%5D%20OR%20%22Abciximab%22%5BMeSH%20Terms%5D","original_query":"\"Abciximab\"[TIAB] OR \"Abciximab\"[MeSH Terms]","retmax":10,"query":"\"Abciximab\"[TIAB] OR \"Abciximab\"[MeSH Terms]","pmids":["30845955","29371038","15987622","38063187","12587933","29217012","19755402","27519521","29217013","36380406"]},{"query_translation":"\"Abemaciclib\"[Title/Abstract]","search_time":"2025-06-29T09:09:40.235","drug_name":"Abemaciclib","translation_set":[],"indication":"* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","status":"success","count":1125,"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abemaciclib%22%5BTIAB%5D%20OR%20%22Abemaciclib%22%5BMeSH%20Terms%5D","original_query":"\"Abemaciclib\"[TIAB] OR \"Abemaciclib\"[MeSH Terms]","retmax":10,"query":"\"Abemaciclib\"[TIAB] OR \"Abemaciclib\"[MeSH Terms]","pmids":["32954927","28968163","28580882","36493792","38729566","39660834","38194616","35337972","31563959","34656740"]}]